- Exclusive non-clinical data have been selected for
presentations at ADA on three of Adocia’s innovative programs:
- AdoShell®, aimed as a curative treatment for people with Type 1
Diabetes by delivering human islets or iPSCs1, is progressing
towards a First-In-Human trial
- AdOral® is an oral delivery technology, that could improve
bioavailability of semaglutide over Rybelsus®, and applicable to a
wide range of therapeutic peptides
- AdoGel® could ensure a sustained release of semaglutide with a
once monthly injection, offering an alternative to today’s once
weekly injection
Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a
clinical-stage biopharmaceutical company focused on the research
and development of innovative therapeutic solutions for the
treatment of diabetes and obesity, is pleased to announce that
exclusive data from three of Adocia’s innovative technology
platforms have been selected for poster presentations at the
upcoming American Diabetes Association’s (ADA) 84th Scientific
Sessions to be held June 21-24, 2024, in Orlando, Florida.
The annual meeting of the ADA is the largest worldwide
scientific meeting for clinicians and researchers in diabetes,
obesity and metabolic disorders.
The abstracts are published online on the journal
Diabetes® website and the ePoster presentations will be
available to conference attendees from Friday, June 21, 2024.
Posters will be displayed in the Poster Hall, West A4-B2.
- AdoShell®, a non-fibrotic encapsulation system for human
islets transplantation shows promising results for clinical
application as a cure for people with Type 1 Diabetes
Xavier Gaume, Romain Besnard, Julie Brun, Nathalie Leclerc,
Camille Gautier, Ouardane Jouannot, Nicolas Laurent, Anne-Lise
Gaffuri, Rosy Eloy, Karim Bouzakri (CEED, Strasbourg, France),
Olivier Soula
- Presentation 1504-P: Saturday, June 22, 12:30 pm-1:30 pm
(ET)
AdoShell® is an easily implantable and fully retrievable
scaffold for islet transplantation aiming to cure diabetes by cell
therapy without requiring immunosuppression. It is based on a
permselective hydrogel film allowing insulin diffusion while
preventing immune cell invasion. Allogenic transplant of rat islets
in immunocompetent diabetic rats has already demonstrated
encapsulated islets survival, insulin secretion, and glycemic
regulation.
Compatibility with human islets, local tolerance, and
scalability to deliver a therapeutic dose were studied to meet
requirements for a first in human. Findings of these studies
demonstrate that AdoShell® Islets is suitable for clinical
evaluation.
- AdOral®, a versatile platform for improved oral peptide
absorption
Gregory Blache, Anne-Lise Gaffuri, Martin Gaudier, Sana Hakim,
Audrey Maréchal, Ulysse Naessens, Romain Noël, Olivier Soula
- Presentation 1677-P: Monday, June 24, 12:30 pm - 01:30
pm (ET)
AdOral® is an oral delivery platform based on non-specific
Mechanism of Action (MoA) via intestine paracellular passage
leading to improved absorption. AdOral®‘s MoA and its permeation
effect were evaluated in vitro and in vivo on several peptides,
including semaglutide, and compared to SNAC (the technology used in
Rybelsus®). AdOral® is a versatile and performant platform that
could lead to oral formulations for a wide range of therapeutic
peptides.
- Development of a once-a-month formulation of Semaglutide
from an innovative injectable and biodegradable hydrogel
Olivier Soula, Claire Mégret, Romain Besnard, Audrey Marechal,
Sana Hakim, Jenny Erales, Ulysse Naessens, Maud Fumex, Martin
Gaudier, Emmanuel Dauty
- Presentation 1674-P: Monday, June 24, 12:30 pm - 1:30 pm
(ET)
AdoGel® is an injectable hydrogel technology consisting of
cross-linked degradable polymers that allows sustained release of
soluble peptides over 1 to 3 months duration. An AdoGel®
formulation of semaglutide was tested in rats. Results showed that
a sustained release of semaglutide over one month is achievable and
could be a real benefit for patient compliance by limiting the
injection frequencies, reducing side effects and improving
efficacy.
Note: all information contained in the submitted abstract should
be considered preliminary and subject to change until the study
data and observations are fully presented at the ADA 84th
Scientific Sessions and is subject to embargo until June 21, 2024,
at 6:30 am ET.
About the American Diabetes Association Scientific
Sessions
The American Diabetes Association’s Scientific Sessions is the
world’s largest diabetes meeting, convening more than 11,000
leading physicians, scientists, researchers and health care
professionals from around the globe. The meeting features the
latest scientific findings in diabetes, including more than 200
sessions and 2,000 original research presentations.
About Adocia
Adocia is a biotechnology company specializing in the discovery
and development of therapeutic solutions in the field of metabolic
diseases, primarily diabetes and obesity.
The company has a broad portfolio of drug candidates based on
four proprietary technology platforms: 1) The BioChaperone®
technology for the development of new generation insulins and
products combining different hormones; 2) AdOral®, an oral peptide
delivery technology; 3) AdoShell®, an immunoprotective biomaterial
for cell transplantation, with an initial application in pancreatic
cells transplantation; and 4) AdoGel®, a long-acting drug delivery
platform.
Adocia holds more than 25 patent families. Based in Lyon, the
company has about 80 employees. Adocia is listed on the regulated
market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).
Disclaimer
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers as being reasonable.
However, there can be no guarantee that the estimates contained in
such forward-looking statements will be achieved, as such estimates
are subject to numerous risks including those set forth in the
“Risk Factors” section of the universal registration document that
was filed with the French Autorité des marchés financiers on April
29, 2024, available at www.adocia.com.
Those risks include uncertainties inherent in Adocia's short- or
medium-term working capital requirements, in research and
development, future clinical data, analyses and the evolution of
economic conditions, the financial markets and the markets in which
Adocia operates, which could impact the Company's short-term
financing requirements and its ability to raise additional
funds.
The forward-looking statements contained in this press release
are also subject to risks not yet known to Adocia or not considered
as material by Adocia at this time. The occurrence of all or part
of such risks could cause the actual results, financial conditions,
performances, or achievements of Adocia be materially different
from those mentioned in the forward-looking statements.
____________
1 iPSCs: induced pluripotent stem cells
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240618032710/en/
Adocia Olivier Soula CEO
contactinvestisseurs@adocia.com +33 (0)4 72 610 610
www.adocia.com
Ulysse Communication Adocia Press & Investor
Relations Bruno Arabian Nicolas Entz
adocia@ulysse-communication.com + 33 (0)6 87 88 47 26
Grafico Azioni Edoc Acquisition (NASDAQ:ADOC)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Edoc Acquisition (NASDAQ:ADOC)
Storico
Da Giu 2023 a Giu 2024
